S. Rutzner

发表

Electronic Support for Retrospective Analysis in the Field of Radiation Oncology: Proof of Principle Using an Example of Fractionated Stereotactic Radiotherapy of 251 Meningioma Patients

H. Prokosch, T. Ganslandt, R. Fietkau, 2017, Front. Oncol..

Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer

H. Iro, A. Hartmann, R. Fietkau, 2021, Cancers.

Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

H. Iro, A. Hinke, A. Hartmann, 2020, Journal for ImmunoTherapy of Cancer.

Differences in and Prognostic Value of Quality of Life Data in Rectal Cancer Patients with and without Distant Metastases

R. Fietkau, L. Distel, S. Rutzner, 2020, Healthcare.

Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma

M. Buchfelder, R. Fietkau, I. Eyüpoglu, 2017, Journal of Neuro-Oncology.

F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial

R. Fietkau, T. Brunner, H. Iro, 2022, Annals of Nuclear Medicine.

Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors

H. Iro, R. Fietkau, Jian-Guo Zhou, 2021, BMC Cancer.

Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.

R. Fietkau, Jian-Guo Zhou, M. Eckstein, 2020, European journal of cancer.

Baseline Quality of Life of Physical Function Is Highly Relevant for Overall Survival in Advanced Rectal Cancer

R. Fietkau, L. Distel, S. Rutzner, 2022, Healthcare.

Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer

H. Iro, A. Hinke, R. Fietkau, 2022, Journal for ImmunoTherapy of Cancer.

Predictive Value of Multiparametric MRI for Response to Single-Cycle Induction Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

M. Uder, H. Iro, R. Fietkau, 2021, Frontiers in Oncology.

R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial

U. Neumann, R. Grützmann, W. Uhl, 2020, Strahlentherapie und Onkologie.

Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors

R. Fietkau, Jian-Guo Zhou, M. Eckstein, 2020, Frontiers in Oncology.

Deterioration of Health-Related Quality of Life Scores under Treatment Predicts Longer Survival

R. Fietkau, L. Distel, S. Rutzner, 2020, BioMed research international.

Transient Enlargement in Meningiomas Treated with Stereotactic Radiotherapy

Yixing Huang, C. Bert, L. Distel, 2022, Cancers.

Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors

R. Fietkau, Jian-Guo Zhou, R. Sun, 2021, Journal for ImmunoTherapy of Cancer.

Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T-cell infiltration.

H. Iro, A. Hinke, T. Brunner, 2021 .

Development of a Flow Cytometry-Based Whole-Blood Prognostic Immune Signature in Metastatic Cancer Patients treated with immune checkpoint inhibitors

R. Fietkau, Jian-Guo Zhou, R. Sun, 2020, medRxiv.

Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors

H. Iro, R. Fietkau, Jian-Guo Zhou, 2021, BMC cancer.